PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

• Status: Not yet recruiting
• Trial end date: 2028-01-04
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the safety of prasugrel monotherapy without aspirin versus 12-month dual antiplatelet therapy (DAPT) in patients with STEMI using platinum-chrome everolimus-eluting stent (PtCr-EES: SYNERGYTM).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kindai University
• Collaborator: Boston Scientific Corporation
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Patients scheduled for primary PCI with everolimus-eluting stent (PtCr-EES, SYNERGYTM)

• STEMI patients

• Patients who can continue dual antiplatelet therapy with aspirin and a P2Y12 inhibitor for 12 months

Exclusion Criteria:

• Patients taking anticoagulants

• Patients under 18 years old

• Patients with less than 1 year prognosis

• Patients participating in other intervention studies